INDICATORS ON COBICISTAT YOU SHOULD KNOW

Hepatic impairment No dose adjustment is necessary in people with delicate or average (Boy or girl-Pugh A or B) hepatic impairment (see segment five.2). Exposure to midostaurin and its active metabolite CGP62221 is substantially reduce in individuals with extreme hepatic impairment than that in sufferers with standard hepatic purpose (see segment 5